MRVI
Maravai Lifesciences Holdings, Inc. Health Care Pharmaceutical Preparations Russell 3000
$7.81Close
$2.83 – $9.0052-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 98 · stronger than 98% of stocks over 12 months
- Volume drying up last 10 days 31% under the 50-day average
Cautions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
13%
1wk
up 6.7%
price change
1mo
up 2.0%
price change
12-month return
up 149%
market up 11% ·
its own up 144%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
down 28%
year on year
EPS growth
—
latest quarter
Sales growth
up 9%
latest quarter · -32 pts
ROE
down 49%
return on equity
Free cash margin
down 38%
-$70.7M FCF
D/E
1.35
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.3%
$0.50 a day · 2×ATR $6.82
RS
98 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.79
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Gross margin narrowing Gross margin fell from 41.8% to 18.3%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 28.3% over the year, from $259.2M to $185.7M.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-3% vs market2 sessions after results
Financials
- Gross 18%
- Net -70%
- Free cash -38%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $284.1M | $799.2M | $883.0M | $288.9M | $259.2M | $185.7M |
| Gross margin | 72% | 82% | 81% | 49% | 42% | 18% |
| Operating income | $119.9M | $554.6M | $574.2M | -$31.6M | -$235.6M | -$215.3M |
| Net income | $89.0M | $469.3M | $490.7M | -$138.4M | -$144.8M | -$130.8M |
| Net margin | 31% | 59% | 56% | -48% | -56% | -70% |
| Earnings per share | $3.08 | $1.82 | $1.92 | -$1.05 | -$1.05 | -$0.91 |
| Free cash flow | $126.8M | $353.7M | $518.9M | $60.7M | -$22.2M | -$70.7M |
| Free cash margin | 45% | 44% | 59% | 21% | -9% | -38% |
| Cash | $236.2M | $551.3M | $632.1M | $575.0M | $322.4M | $216.9M |
| Long-term debt | $528.6M | $524.6M | $522.0M | $518.7M | $290.5M | $286.3M |
| Shareholders' equity | $88.5M | $315.5M | $545.2M | $416.8M | $325.3M | $212.4M |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 7, 2026 | Quarterly ↗ | Jun 30, 2026 | 38d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 18, 2025 | Annual ↗ | Dec 31, 2024 | 77d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jun 3, 2026 | Material agreement · Agreement ended · New obligation · Regulation FD ↗ |
| May 29, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Feb 25, 2026 | Results ↗ |
| Nov 6, 2025 | Results ↗ |
| Oct 27, 2025 | Director or officer change ↗ |
| Aug 11, 2025 | Results · Restructuring · Director or officer change ↗ |
| Jul 18, 2025 | Auditor change ↗ |
| Jun 25, 2025 | Director or officer change · Regulation FD ↗ |
| Jun 9, 2025 | Director or officer change · Regulation FD ↗ |
| May 28, 2025 | Shareholder vote ↗ |